Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.59 |
| ▸ | SRC | P12931 | 8/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | FCER2 | P06734 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 4/20 | 0.45 |
| ▸ | FYN | P06241 | 4/20 | 0.45 |
| ▸ | YES1 | P07947 | 4/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361802 | 0.88 | SRC (0.54) | KDRSRCCDK2NTRK1FCER2 | |
| SCHEMBL5362945 | 0.81 | MOGAT2 (0.53) | KDRPDPK1 | |
| SCHEMBL7140809 | 0.81 | SRC (0.54) | KDRSRCCDK2NTRK1FCER2 | |
| SCHEMBL5363755 | 0.80 | PDPK1 (0.66) | KDRSRCCDK2NTRK1FCER2 | |
| SCHEMBL5358229 | 0.80 | LRRK2 (0.64) | KDRSRCCDK2NTRK1AURKA | |
| SCHEMBL5363032 | 0.79 | SRC (0.54) | KDRSRCCDK2NTRK1FCER2 | |
| SCHEMBL5364961 | 0.79 | MAP1LC3B (0.67) | SRCCDK2NTRK1AURKA | |
| SCHEMBL7132893 | 0.78 | SRC (0.55) | KDRSRCCDK2NTRK1FCER2 | |
| SCHEMBL5357946 | 0.78 | RET (0.64) | KDRSRCCDK2NTRK1FCER2 | |
| SCHEMBL5365553 | 0.77 | PLK4 (0.53) | KDRSRCCDK2NTRK1FCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | KDR 239/4885SRC 189/4885CDK2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.